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SYNOPSIS 
 
The thesis entiteled “Application of desymmetrization towards the synthesis of natural 
products: Saliniketals, Venturicidin-X and Emericellamide B” is divided into three 
chapters. 
CHAPTER I: Formal total synthesis of (–)-saliniketals A and B:       
Section A:  This section deals with application of desymmetrization technique in 
asymmetric synthesis and description of earlier synthetic approaches of 
(–)-Saliniketals A and B.  
Section B: This section describes the formal total synthesis of (–)-saliniketals A and 
B.       
CHAPTER II: Synthesis of C15-C27 fragment of Venturicidin X: 
Section A: This section brings flavor of some biologically active antibiotic 
molecules and earlier synthetic approaches towards the synthesis of C15-
C27 fragment of Venturicidin X. 
Section B: This section projects the synthesis of C15-C27 fragment of Venturicidin 
X. 
CHAPTER III: Formal total synthesis of Emericellamide B: 
Section A: This section deals with the introduction and earlier synthetic approach 
for the synthesis of Emericellamide B. 
Section B:  This section describes the formal total synthesis of Emericellamide B. 
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CHAPTER-I 
Section A: Desymmetrization technique in asymmetric synthesis and description of 
earlier synthetic approaches of (–)-Saliniketals A and B. 
The journey of development of life saving organic compound (drug) started in the twentieth 
century. Modern drug discovery has consisted of a series of thematic development that began 
with isolation and identifying the active ingredients from traditional medicines or by 
serendipitous discovery. Very often natural abundance of active natural products is very low.  
For their further studies and clinical trial, its laboratory synthesis is essential from an easily 
available chief starting intermediate. The chemical syntheses of natural molecules without the 
aid of enzymes often present formidable challenges to human ingenuity and skill. The structure 
of natural products in an almost infinite range of complexity and stability therefore often 
present distinct synthetic problems, which require strategies and tactics for their solutions. It is 
the almost unlimited variation in structure and the constant discovery of new molecular 
constructs that keep the field of natural products syntheses so attractive and vibrant. The 
dazzling biological properties exhibited by many natural products and the attendant 
opportunities these molecules offer for probing biological questions also serve as major 
attractions in this field of investigation. 
 
Section B: Formal Total Synthesis of (–)-Saliniketals A and B: 
Saliniketals A (1) and B (2) are bicyclic polyketides isolated in 2007 by Fanical and co-workers 
from marine actinomycete Salinispora arenicola. They inhibit ornithine decarboxylase (ODC) 
induction. Such ODC inhibitors may be used as valuable chemotherapeutic agents for cancer. 
Saliniketals A and B possesses a 2,8-dioxabicyclo[3.2.1]octane ring featuring a elaborate side 
chain at C11 that terminates in an unsaturated primary amide. The interesting molecular frame 
work combined with promising biological activity makes them an attractive target for total 
synthesis (Figure 1).  
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The details of our approach towards the synthesis of Saliniketals A and B are described in 
scheme 1, which illustrates that they both could be accessed from a common intermediate 3, 
which in turn could be obtained from 4 and 5 via Pirrung-Heathcock anti-aldol reaction 
condition. Intermediate 4 could be obtained by an intramolecular Wacker type cyclization of 
the olifine 6. The compound 6 could be obtaibed from a known bicyclic intermediate 7, which 
in turn could be obtained from furan and 2,4-dibromo-3-pentanone following seven steps 
reaction sequence. 
 Retrosynthetic Analysis of (–)-Saliniketals A and B.         
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1 
            We commenced our synthesis from intermediate 7, which could be obtained by the 
following sequence, Zn-Cu couple mediated [4+3] cycloaddition between 2,4-dibromo-3-
pentanone and furan to form 2,4-dimethyl-8-oxabicyclo[3.2.1]oct-6-ene-3-one, DIBAL-H 
reduction, benzyl protection, chiral hydroboration, PCC mediated oxidation, Bayer-Villeger 
oxidation, followed by diastereoselective methylation afforded 7 (Scheme 3). 
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Scheme 2 
Acid catalysed methanolysis of bicyclic lactone 7 proceeded smoothly to furnish ester 14. LAH 
mediated reduction of ester followed by IBX oxidation in DMSO afforded aldehyde 15. 
Substrate controlled Grignard reaction with protected bromo ketone 16 in THF afforded 
 
 
 
 
 
 
 
Scheme 3 
Felkin-Anh alcohol 17 with good selectivity (86:14 by HPLC). Compound 17 upon treatment 
with BF3.Et2O in CH2Cl2 afforded a new compound 18 instead of 4 (Scheme 4). To avoid the 
protecting group manipulation, we chose Grignard reaction of 15 with 1-butenylmagnesium 
bromide in THF afforded 19. This time we got even better yield and better selectivity (96:4 by 
HPLC).  
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Scheme 4 
The absolute stereochemistry of the newly introduced chiral centre was determined at a later 
stage of synthesis. The hydroxyl group was protected as its acetate derivative and upon 
treatment with aqueous acetic acid furnished hemicaetal 20. Lithium borohydride mediated 
reduction followed by selective protection with TBDPSCl and Imidazole afforded 6 (Scheme 
5). 
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Scheme 6 
 Intrtamolecular Wacker type cyclization of 6 with catalytic amount of PdCl2 and CuCl2 under 
oxygen atmosphere proceeded smoothly to produce bicyclic acetal 21 with good yield. The 
silyl protecting group was removed with 1(M) solution of TBAF in THF and the resulting 
alcohol was oxidized to corresponding aldehyde 4 using IBX. The aldehyde 4 on ant-aldol 
reaction with ester 5 following Pirrung-Heathcock protocol afforded 22 in good yield and with 
good anti selectivity (96:4 by HPLC).  
X-Ray Crystal Structure of 23. 
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Catalytic hydrogenation of compound 22 followed by acetonide protection afforded compound 
23 whose NOE correlation and 13C value at 100.6 ppm supports the anti geometry between C7 
and C9 hydroxy group. The single crystal X-ray crystallographic analysis unambiguously 
confirmed its relative and absolute stereochemistry (Figure 2). Reduction of compound 23 
using LAH in THF afforded an advanced common intermediate 3 (Scheme 6). The spectral 
analytical data of 3 {[α]D25 +6.1 (c 1.24 CHCl3); lit. [α]D25 +6.2 (c 0.81 CHCl3)} were in good 
agreement with the reported values by Paterson et al.  
 
CHAPTER-II 
Section A: This Section Deals With The Importance of Some Biologically Active 
Antibiotic Molecules and Earlier Synthetic Approaches Towards The 
Synthesis of C15-C27 Fragment of Venturicidin X. 
Discovery of antibiotics is the greatest achievement of 20th century. They are the drug 
molecules derived wholly or partially from certain microorganisms and are used to treat 
bacterial or fungal infections. They are ineffective against virus. They kill either microorganism 
or stop them from reproducing, allowing the body’s natural defense to eliminate them. The 
effectiveness of the treatment depends on how well the drug is absorbed into the bloodstream, 
how much of the drug reaches the sites of infection in the body, and how quickly the body 
eliminates the drug. 
Several hundreds of compounds with antibiotic activity have been isolated from 
microorganisms or synthesized in laboratory over few decades, but only a few of them like 
Erythromycin, Azithromycin, Telithromycin, Tetracyclines etc. are clinically useful, and others 
are not, because most of them are toxic to human body. 
Mutation of bacteria, like other living organism over time in response to environmental 
challenges is a common phenomenon and hence resistance of bacteria to antibiotics is an 
unavoidable side effect of their use. Thus introduction of a new antibiotic molecule by isolation 
or modifications of natural or synthetic antibiotics have become a challenging task to synthetic 
organic chemist.    
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Section B: Synthesis of C15-C27 Fragment of Venturicidins: 
Venturicidin A, B and its aglycon Venturicidin X are 20-membered macrolide antibiotics were 
isolated from several streptomyces. Their structure and absolute configuration were elucidated 
by chemical degradation, spectroscopic correlation and X-ray crystallographic analysis. They 
show strong activity against a number of plant pathogenic fungi and mitochondrial H+ATPase. 
Among all nine stereocentres within Venturicidin-X (Figure 3), alternate 1,3,5-anti-methyl 
substitutions is quite challenging and we have interested to apply our desymmetrization 
protocol for the synthesis of C15-C27 fragment of venturicidin X. 
 
 
 
 
Figure 3 
Our primary synthetic strategy divided the macrolide Venturicidin X into two major segments, 
acid C1-C14 (25) and alcohol C15-C27 (26), which could be coupled by esterification followed 
by intramolecular Wittig-Hornor condensation (Scheme 7).  
Retrosynthetic analysis of venturicidin X. 
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The C15-C27 fragment could be obtained from intermediate 27 via Sharples asymmetric 
epoxidation followed by TBDMSOTf mediated rearrangement. Intermediate 27 could be 
obtained from highly substituted alcohol 28 via standard reaction procedure. 28 could be 
obtained from substrate controlled Grignard reaction with highly substituted aldehyde 29 and 
ethylmagnesium bromide. The synthesis of lactone 29 already been depicted in previous 
chapter.  
Synthetic strategy for the C15-C27 unit of venturicidin X.  
 
 
 
 
 
 
Scheme 8 
The synthesis of C15-C27 fragment (26) of venturicidin X was envisaged from a highly 
substituted known aldehyde 29, widely used by our group for the synthesis of various 
biologically active natural products (Scheme 8). 
The synthesis was commenced from aldehyde 29 whose synthesis has already been disclosed in 
the previous chapter. The highly substituted aldehyde 29 under Grignard reaction condition 
with ethyl magnesium bromide yielded Felkin-Anh alcohol 28. The newly generated alcohol 
was converted to its acetate derivative 30 and the anomeric methyl group was removed with 
60% acetic acid followed by TEMPO mediated oxidation yielded lactone 31. The axial α-
methyl centre was isomerized to equatorial isomer 32 with DBU as non nucleofillic base 
(Scheme 9).  
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Scheme 9 
LAH mediated reduction of lactone 32 yielded mono protected triol which on acetonide 
protection furnished 33. Hydrogenation of compound 33 followed by selective primary 
protection with TBDMSCl and immidazole yielded compound 34. The secondary hydroxyl 
group was converted to its xanthete ester followed by treatment with Bu3SnH and catalytic 
amount AIBN furnished 35. Desilylation of compound 35 using TBAF in THF yielded 
compound 36 (Scheme 10).  
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The primary hydroxyl group was oxidised to aldehyde which on Wittig olefination yielded 27. 
The α,β- unsaturated ester was reduced with DIBAL-H in CH2Cl2 at –78 oC and the resulting 
allylic alcohol on Sharpless epoxidation condition yielded 37. This epoxy alcohol on treatment 
with TBDMSOTf and DIPEA at –78 oC yielded rearranged aldehyde 38. The aldehyde on 
Wittig homologation with Ph3P=CHCO2Et in refluxing benzene afforded olefin which on 
hydrogenation yielded 39 (Scheme 11).  
 
 
 
 
 
 
 
 
 
 
 Scheme 11 
 
The ester was converted to lactone 40 upon treatment with catalytic PPTS in CH2Cl2:MeOH 
(10:1). Diastereoselective methylation of 40 with LDA and MeI in THF at –78 oC yielded 41 in 
good yield. The lactone was reduced to diol using LAH in THF and the primary hydroxyl 
group was selectively protected with TBDMSCl and Imidazole in CH2Cl2 yielded the desired 
product 26 in good yield (Scheme 12).  
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Scheme 12 
The spectral analytical data of 26 {[α]D25 +35.0 (c 1.2 CHCl3); lit. [α]D24 +33.6 (c 2.09 CHCl3)} 
were in good agreement with the reported literature. Thus we have completed the C15-C27 
segment of venturicidin X following twenty three steps liner sequence starting from a known 
intermediate 29 and efforts to complete the synthesis of C1-C14 fragment with minor 
manipulations are in progress in our group. 
 
CHAPTER-III 
Section A: Introduction and Earlier Synthetic Approach for Emericellamide B. 
Emericellamide A (42) and B (43) (Figure 4) are the two cyclic depsipeptide were isolated in 
2007 from marine fungus Emericella sp. The planar structure of these two depsipeptides were 
assigned by the application of Merfy’s method, J-based coupling constant analysis and   
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modified Mosher method. They both show antibacterial activities against methicillin-resistant 
Staphilococcus aureus with MIC value 3.8 and 6.0 µM respectively. The interesting chemical 
structure and impressive biological activity has made them attractive target for total synthesis. 
To date only one total synthesis of Emericellamide B (43) has been reported by Tao Ye et. al. 
Section B:  Formal Total Synthesis of Emericellamide B: 
The detail of our approach towards the synthesis of Emericellamide B is depicted in Scheme 
13. Disconnection of the emericellamide B (43) at the two alanine residues would give an 
advanced intermediate 44 which on further fragmentations would provide tetrapeptide 45 and a 
polyketides 46. The tetrapeptide 45 could be obtained following standard peptide coupling 
protocol starting from commercially available protected L-amino acids and the polyketide 
fragment 46 could be envisaged following desymmetrization protocol to afford four chiral 
centers starting from a known bicyclic lactone 48 which in turn could be obtained from 10 via 
desymmetrization with chiral hydroborane.  
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Tetrapeptide 45 was synthesized from commercially available protected L-amino acids. The 
coupling of Cbz-leu-OH (49) with H-ala-OtBu ester using EDCI and HOBt afforded the 
dipeptide 50. Deprotection of the Cbz-group with Pd-C (10%) in ethyl acetate under hydrogen 
atmosphere followed by coupling with Cbz-val-OH afforded the tripeptide 51. Following the 
same sequence of reactions, 45 was obtained in good yield (Scheme 14). 
 
 
 
 
 
 
 
Scheme 14 
The synthesis of 46 was initiated from a known bicyclic intermediate 48, which in turn could 
be prepared from 10 following desymmetrization with chiral (+)-Ipc2BH, PCC mediated 
oxidation, Bayer-Villiger reaction, and diastereoselective methylation (Scheme 15). 
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Reduction of the bicyclic lactone 48 with LAH in THF furnished mono-protected triol and the 
1,3-diol moiety was protected with acetonide to afford 55. The primary hydroxyl group was 
converted to its TBS-ether using TBDMSCl and imidazole in CH2Cl2 followed by deprotection 
of the benzyl-ether with Pd/C (10%) under hydrogen atmosphere gave 56. The secondary 
hydroxyl group was converted to its xanthate derivative and subsequent treatment with Bu3SnH 
in presence of catalytic amount of AIBN afforded 57. Desilylation of 57 with TBAF in THF 
provided alcohol and the primary hydroxyl group was oxidized with IBX in DMSO and THF 
furnished aldehyde 47. Wittig homologation yielded olefin which on treatment with catalytic 
amount of Pd-C (10%) under hydrogen atmosphere afforded 58 (Scheme 16). 
 
 
 
 
 
 
 
 
 
Scheme 16 
The acetonide was deprotected using 6N HCl in ethyl acetate provided diol and the primary 
hydroxyl was selectively silylated with TBDMSCl and imidazole to obtain the TBS-ether 59. 
Esterification of the Boc-ala-OH with 59 using EDCI and DMAP followed by desilylation with 
CSA afforded 60. The primary hydroxyl group was converted to acid following TEMPO 
mediated oxidation to furnish 46. The acid 46 was activated with EDCI in presence of HOBt 
and the amine 45 was coupled to obtain our desired product 44 (Scheme 17).  
48
O
O
OBn
O
O OHOBnO
55
1. LAH, THF
2. 2,2-DMP, 
    CH2Cl2
O OTBDMSOHO2. H2, Pd-C(10%)
1. TBDMSCl, Imid,
    CH2Cl2
1. NaHMDS, CS2, MeI
2. Bu3SnH, AIBN, PhH O OTBDMSO
CHO
O O
O O
56
57
47
58
1. TBAF, THF
2. IBX, DMSO-THF
1. Ph3PC5H11Br, 
    NaHMDS,THF
2. H2, Pd-C(10%)
                                                                                                                                                      Synopsis 
 
16 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 17 
In conclusion, we have achieved the formal total synthesis of Emericellamide B from a bicyclic 
precursor in fifteen longest linear steps in a convergent fashion which reconfirmed the absolute 
stereochemistry of Emericellamide B. 
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